nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—ADRA2A—type 2 diabetes mellitus	0.351	1	CbGaD
Phentolamine—ADRA1D—Bromocriptine—type 2 diabetes mellitus	0.088	0.214	CbGbCtD
Phentolamine—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.0799	0.194	CbGbCtD
Phentolamine—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.0758	0.184	CbGbCtD
Phentolamine—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.0641	0.156	CbGbCtD
Phentolamine—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0527	0.128	CbGbCtD
Phentolamine—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0506	0.123	CbGbCtD
Phentolamine—NISCH—islet of Langerhans—type 2 diabetes mellitus	0.000976	0.0824	CbGeAlD
Phentolamine—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000942	0.0795	CbGeAlD
Phentolamine—Naphazoline—ADRA2A—type 2 diabetes mellitus	0.000787	1	CrCbGaD
Phentolamine—NISCH—nephron tubule—type 2 diabetes mellitus	0.000786	0.0663	CbGeAlD
Phentolamine—NISCH—pancreas—type 2 diabetes mellitus	0.000686	0.0579	CbGeAlD
Phentolamine—NISCH—cortex of kidney—type 2 diabetes mellitus	0.000672	0.0568	CbGeAlD
Phentolamine—NISCH—adipose tissue—type 2 diabetes mellitus	0.000622	0.0525	CbGeAlD
Phentolamine—ADRA1B—kidney—type 2 diabetes mellitus	0.000589	0.0497	CbGeAlD
Phentolamine—SIGMAR1—islet of Langerhans—type 2 diabetes mellitus	0.000568	0.0479	CbGeAlD
Phentolamine—Diarrhoea—Linagliptin—type 2 diabetes mellitus	0.000497	0.00371	CcSEcCtD
Phentolamine—Orthostatic hypotension—Irbesartan—type 2 diabetes mellitus	0.000494	0.00368	CcSEcCtD
Phentolamine—Abdominal pain upper—Irbesartan—type 2 diabetes mellitus	0.000494	0.00368	CcSEcCtD
Phentolamine—Hypertension—Pioglitazone—type 2 diabetes mellitus	0.000493	0.00368	CcSEcCtD
Phentolamine—Asthenia—Nateglinide—type 2 diabetes mellitus	0.000488	0.00364	CcSEcCtD
Phentolamine—Chest pain—Pioglitazone—type 2 diabetes mellitus	0.000486	0.00363	CcSEcCtD
Phentolamine—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.000485	0.00362	CcSEcCtD
Phentolamine—Dizziness—Tolazamide—type 2 diabetes mellitus	0.000485	0.00362	CcSEcCtD
Phentolamine—Diarrhoea—Acarbose—type 2 diabetes mellitus	0.000482	0.0036	CcSEcCtD
Phentolamine—Angina pectoris—Metformin—type 2 diabetes mellitus	0.000482	0.0036	CcSEcCtD
Phentolamine—Bradycardia—Gliclazide—type 2 diabetes mellitus	0.000482	0.0036	CcSEcCtD
Phentolamine—Gastrointestinal pain—Repaglinide—type 2 diabetes mellitus	0.000481	0.00359	CcSEcCtD
Phentolamine—Pruritus—Nateglinide—type 2 diabetes mellitus	0.000481	0.00359	CcSEcCtD
Phentolamine—Hypertension—Glimepiride—type 2 diabetes mellitus	0.000481	0.00358	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Rosiglitazone—type 2 diabetes mellitus	0.00048	0.00358	CcSEcCtD
Phentolamine—Nausea—Tolbutamide—type 2 diabetes mellitus	0.000479	0.00357	CcSEcCtD
Phentolamine—Hypertension—Sitagliptin—type 2 diabetes mellitus	0.000479	0.00357	CcSEcCtD
Phentolamine—Nasal congestion—Ramipril—type 2 diabetes mellitus	0.000479	0.00357	CcSEcCtD
Phentolamine—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.000466	0.00348	CcSEcCtD
Phentolamine—Abdominal pain—Repaglinide—type 2 diabetes mellitus	0.000465	0.00347	CcSEcCtD
Phentolamine—Diarrhoea—Nateglinide—type 2 diabetes mellitus	0.000465	0.00347	CcSEcCtD
Phentolamine—Orthostatic hypotension—Losartan—type 2 diabetes mellitus	0.000464	0.00346	CcSEcCtD
Phentolamine—Headache—Tolazamide—type 2 diabetes mellitus	0.00046	0.00343	CcSEcCtD
Phentolamine—Headache—Chlorpropamide—type 2 diabetes mellitus	0.00046	0.00343	CcSEcCtD
Phentolamine—Nervous system disorder—Pioglitazone—type 2 diabetes mellitus	0.000457	0.00341	CcSEcCtD
Phentolamine—SIGMAR1—nephron tubule—type 2 diabetes mellitus	0.000457	0.0386	CbGeAlD
Phentolamine—Angina pectoris—Irbesartan—type 2 diabetes mellitus	0.000455	0.00339	CcSEcCtD
Phentolamine—Headache—Linagliptin—type 2 diabetes mellitus	0.000455	0.00339	CcSEcCtD
Phentolamine—Dizziness—Nateglinide—type 2 diabetes mellitus	0.000449	0.00335	CcSEcCtD
Phentolamine—Vomiting—Acarbose—type 2 diabetes mellitus	0.000448	0.00334	CcSEcCtD
Phentolamine—Nervous system disorder—Sitagliptin—type 2 diabetes mellitus	0.000444	0.00331	CcSEcCtD
Phentolamine—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.000443	0.00331	CcSEcCtD
Phentolamine—Flushing—Gliclazide—type 2 diabetes mellitus	0.000439	0.00328	CcSEcCtD
Phentolamine—Paraesthesia—Glipizide—type 2 diabetes mellitus	0.000437	0.00326	CcSEcCtD
Phentolamine—NISCH—liver—type 2 diabetes mellitus	0.000436	0.0369	CbGeAlD
Phentolamine—Nausea—Tolazamide—type 2 diabetes mellitus	0.000436	0.00325	CcSEcCtD
Phentolamine—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.000436	0.00325	CcSEcCtD
Phentolamine—Hypertension—Bromocriptine—type 2 diabetes mellitus	0.000433	0.00323	CcSEcCtD
Phentolamine—Vomiting—Nateglinide—type 2 diabetes mellitus	0.000432	0.00322	CcSEcCtD
Phentolamine—Angina pectoris—Losartan—type 2 diabetes mellitus	0.000428	0.00319	CcSEcCtD
Phentolamine—Hypotension—Glimepiride—type 2 diabetes mellitus	0.000424	0.00317	CcSEcCtD
Phentolamine—Arrhythmia—Gliclazide—type 2 diabetes mellitus	0.000423	0.00316	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.00042	0.00313	CcSEcCtD
Phentolamine—Nausea—Acarbose—type 2 diabetes mellitus	0.000419	0.00312	CcSEcCtD
Phentolamine—Pain—Glipizide—type 2 diabetes mellitus	0.000416	0.0031	CcSEcCtD
Phentolamine—Pruritus—Repaglinide—type 2 diabetes mellitus	0.000416	0.0031	CcSEcCtD
Phentolamine—Acute coronary syndrome—Irbesartan—type 2 diabetes mellitus	0.000411	0.00306	CcSEcCtD
Phentolamine—Myocardial infarction—Irbesartan—type 2 diabetes mellitus	0.000408	0.00304	CcSEcCtD
Phentolamine—Paraesthesia—Glimepiride—type 2 diabetes mellitus	0.000408	0.00304	CcSEcCtD
Phentolamine—Nausea—Nateglinide—type 2 diabetes mellitus	0.000404	0.00301	CcSEcCtD
Phentolamine—Cardiac disorder—Valsartan—type 2 diabetes mellitus	0.000404	0.00301	CcSEcCtD
Phentolamine—Bradycardia—Metformin—type 2 diabetes mellitus	0.000403	0.00301	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.000403	0.003	CcSEcCtD
Phentolamine—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.000403	0.003	CcSEcCtD
Phentolamine—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.000402	0.003	CcSEcCtD
Phentolamine—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.0004	0.00298	CcSEcCtD
Phentolamine—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000399	0.00298	CcSEcCtD
Phentolamine—SIGMAR1—pancreas—type 2 diabetes mellitus	0.000399	0.0337	CbGeAlD
Phentolamine—Orthostatic hypotension—Ramipril—type 2 diabetes mellitus	0.000398	0.00297	CcSEcCtD
Phentolamine—Abdominal pain upper—Ramipril—type 2 diabetes mellitus	0.000398	0.00297	CcSEcCtD
Phentolamine—Gastrointestinal pain—Glipizide—type 2 diabetes mellitus	0.000398	0.00297	CcSEcCtD
Phentolamine—Angiopathy—Valsartan—type 2 diabetes mellitus	0.000395	0.00294	CcSEcCtD
Phentolamine—Pruritus—Rosiglitazone—type 2 diabetes mellitus	0.000393	0.00293	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.000392	0.00293	CcSEcCtD
Phentolamine—Mediastinal disorder—Valsartan—type 2 diabetes mellitus	0.000392	0.00292	CcSEcCtD
Phentolamine—SIGMAR1—cortex of kidney—type 2 diabetes mellitus	0.000391	0.033	CbGeAlD
Phentolamine—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.000391	0.00292	CcSEcCtD
Phentolamine—Mediastinal disorder—Orlistat—type 2 diabetes mellitus	0.000387	0.00289	CcSEcCtD
Phentolamine—Pain—Sitagliptin—type 2 diabetes mellitus	0.000387	0.00289	CcSEcCtD
Phentolamine—Abdominal pain—Glipizide—type 2 diabetes mellitus	0.000385	0.00287	CcSEcCtD
Phentolamine—Hypotension—Bromocriptine—type 2 diabetes mellitus	0.000383	0.00286	CcSEcCtD
Phentolamine—Bradycardia—Irbesartan—type 2 diabetes mellitus	0.000381	0.00284	CcSEcCtD
Phentolamine—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.00038	0.00284	CcSEcCtD
Phentolamine—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000374	0.00279	CcSEcCtD
Phentolamine—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	0.000371	0.00277	CcSEcCtD
Phentolamine—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	0.00037	0.00276	CcSEcCtD
Phentolamine—Headache—Repaglinide—type 2 diabetes mellitus	0.000369	0.00275	CcSEcCtD
Phentolamine—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	0.000368	0.00274	CcSEcCtD
Phentolamine—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000368	0.00274	CcSEcCtD
Phentolamine—Flushing—Metformin—type 2 diabetes mellitus	0.000368	0.00274	CcSEcCtD
Phentolamine—Cardiac disorder—Metformin—type 2 diabetes mellitus	0.000368	0.00274	CcSEcCtD
Phentolamine—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.000367	0.00274	CcSEcCtD
Phentolamine—Angina pectoris—Ramipril—type 2 diabetes mellitus	0.000367	0.00274	CcSEcCtD
Phentolamine—SIGMAR1—adipose tissue—type 2 diabetes mellitus	0.000362	0.0306	CbGeAlD
Phentolamine—Angiopathy—Metformin—type 2 diabetes mellitus	0.000359	0.00268	CcSEcCtD
Phentolamine—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.000359	0.00268	CcSEcCtD
Phentolamine—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.000359	0.0303	CbGeAlD
Phentolamine—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.000358	0.00267	CcSEcCtD
Phentolamine—Mediastinal disorder—Metformin—type 2 diabetes mellitus	0.000357	0.00266	CcSEcCtD
Phentolamine—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000356	0.00265	CcSEcCtD
Phentolamine—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000356	0.03	CbGeAlD
Phentolamine—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000354	0.00264	CcSEcCtD
Phentolamine—Chest pain—Gliclazide—type 2 diabetes mellitus	0.000351	0.00262	CcSEcCtD
Phentolamine—Hypotension—Glyburide—type 2 diabetes mellitus	0.00035	0.00261	CcSEcCtD
Phentolamine—Nausea—Repaglinide—type 2 diabetes mellitus	0.000349	0.00261	CcSEcCtD
Phentolamine—Asthenia—Glipizide—type 2 diabetes mellitus	0.000349	0.00261	CcSEcCtD
Phentolamine—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000348	0.0026	CcSEcCtD
Phentolamine—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.000347	0.00259	CcSEcCtD
Phentolamine—Flushing—Irbesartan—type 2 diabetes mellitus	0.000347	0.00259	CcSEcCtD
Phentolamine—Pruritus—Glipizide—type 2 diabetes mellitus	0.000344	0.00257	CcSEcCtD
Phentolamine—Angiopathy—Irbesartan—type 2 diabetes mellitus	0.000339	0.00253	CcSEcCtD
Phentolamine—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000338	0.0286	CbGeAlD
Phentolamine—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.000337	0.00251	CcSEcCtD
Phentolamine—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.000336	0.00251	CcSEcCtD
Phentolamine—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.000335	0.0025	CcSEcCtD
Phentolamine—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000335	0.0025	CcSEcCtD
Phentolamine—Arrhythmia—Irbesartan—type 2 diabetes mellitus	0.000334	0.00249	CcSEcCtD
Phentolamine—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000333	0.00248	CcSEcCtD
Phentolamine—Acute coronary syndrome—Ramipril—type 2 diabetes mellitus	0.000331	0.00247	CcSEcCtD
Phentolamine—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00033	0.00246	CcSEcCtD
Phentolamine—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.00033	0.00246	CcSEcCtD
Phentolamine—Myocardial infarction—Ramipril—type 2 diabetes mellitus	0.000329	0.00246	CcSEcCtD
Phentolamine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000328	0.00245	CcSEcCtD
Phentolamine—Flushing—Losartan—type 2 diabetes mellitus	0.000327	0.00244	CcSEcCtD
Phentolamine—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000326	0.00243	CcSEcCtD
Phentolamine—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000325	0.00242	CcSEcCtD
Phentolamine—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000324	0.00242	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000323	0.00241	CcSEcCtD
Phentolamine—Chest pain—Valsartan—type 2 diabetes mellitus	0.000322	0.0024	CcSEcCtD
Phentolamine—Dizziness—Glipizide—type 2 diabetes mellitus	0.000322	0.0024	CcSEcCtD
Phentolamine—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000321	0.0024	CcSEcCtD
Phentolamine—Angiopathy—Losartan—type 2 diabetes mellitus	0.000319	0.00238	CcSEcCtD
Phentolamine—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000319	0.00238	CcSEcCtD
Phentolamine—Chest pain—Orlistat—type 2 diabetes mellitus	0.000319	0.00238	CcSEcCtD
Phentolamine—ADRA2C—kidney—type 2 diabetes mellitus	0.000315	0.0266	CbGeAlD
Phentolamine—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000314	0.00234	CcSEcCtD
Phentolamine—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000314	0.00234	CcSEcCtD
Phentolamine—ADRA2C—pancreas—type 2 diabetes mellitus	0.000313	0.0265	CbGeAlD
Phentolamine—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000311	0.00232	CcSEcCtD
Phentolamine—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.00031	0.00231	CcSEcCtD
Phentolamine—Vomiting—Glipizide—type 2 diabetes mellitus	0.000309	0.00231	CcSEcCtD
Phentolamine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000308	0.0023	CcSEcCtD
Phentolamine—ADRA2C—cortex of kidney—type 2 diabetes mellitus	0.000307	0.0259	CbGeAlD
Phentolamine—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000306	0.00229	CcSEcCtD
Phentolamine—Headache—Glipizide—type 2 diabetes mellitus	0.000305	0.00227	CcSEcCtD
Phentolamine—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000303	0.00226	CcSEcCtD
Phentolamine—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000302	0.00225	CcSEcCtD
Phentolamine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.0003	0.00224	CcSEcCtD
Phentolamine—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000299	0.00223	CcSEcCtD
Phentolamine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000299	0.00223	CcSEcCtD
Phentolamine—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000298	0.0252	CbGeAlD
Phentolamine—Hypertension—Metformin—type 2 diabetes mellitus	0.000298	0.00222	CcSEcCtD
Phentolamine—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000296	0.00221	CcSEcCtD
Phentolamine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000294	0.00219	CcSEcCtD
Phentolamine—Chest pain—Metformin—type 2 diabetes mellitus	0.000294	0.00219	CcSEcCtD
Phentolamine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000292	0.00218	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00029	0.00217	CcSEcCtD
Phentolamine—Nausea—Glipizide—type 2 diabetes mellitus	0.000289	0.00216	CcSEcCtD
Phentolamine—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000289	0.00215	CcSEcCtD
Phentolamine—Hypotension—Valsartan—type 2 diabetes mellitus	0.000289	0.00215	CcSEcCtD
Phentolamine—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000288	0.00215	CcSEcCtD
Phentolamine—Pain—Gliclazide—type 2 diabetes mellitus	0.000288	0.00215	CcSEcCtD
Phentolamine—Headache—Glimepiride—type 2 diabetes mellitus	0.000285	0.00212	CcSEcCtD
Phentolamine—ADRA2C—adipose tissue—type 2 diabetes mellitus	0.000284	0.024	CbGeAlD
Phentolamine—Headache—Sitagliptin—type 2 diabetes mellitus	0.000284	0.00212	CcSEcCtD
Phentolamine—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000281	0.0021	CcSEcCtD
Phentolamine—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.00028	0.00209	CcSEcCtD
Phentolamine—Flushing—Ramipril—type 2 diabetes mellitus	0.00028	0.00209	CcSEcCtD
Phentolamine—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000278	0.00207	CcSEcCtD
Phentolamine—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000277	0.00207	CcSEcCtD
Phentolamine—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000276	0.00206	CcSEcCtD
Phentolamine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000275	0.00205	CcSEcCtD
Phentolamine—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000274	0.00205	CcSEcCtD
Phentolamine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000272	0.00203	CcSEcCtD
Phentolamine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000271	0.00202	CcSEcCtD
Phentolamine—Nausea—Glimepiride—type 2 diabetes mellitus	0.00027	0.00201	CcSEcCtD
Phentolamine—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000269	0.00201	CcSEcCtD
Phentolamine—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000269	0.00201	CcSEcCtD
Phentolamine—Asthenia—Glyburide—type 2 diabetes mellitus	0.000269	0.002	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000267	0.00199	CcSEcCtD
Phentolamine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000266	0.00198	CcSEcCtD
Phentolamine—Pruritus—Glyburide—type 2 diabetes mellitus	0.000265	0.00198	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000264	0.00197	CcSEcCtD
Phentolamine—Hypotension—Metformin—type 2 diabetes mellitus	0.000263	0.00196	CcSEcCtD
Phentolamine—Pain—Orlistat—type 2 diabetes mellitus	0.000261	0.00195	CcSEcCtD
Phentolamine—Chest pain—Losartan—type 2 diabetes mellitus	0.000261	0.00194	CcSEcCtD
Phentolamine—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000261	0.00194	CcSEcCtD
Phentolamine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.00026	0.00194	CcSEcCtD
Phentolamine—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000259	0.00193	CcSEcCtD
Phentolamine—Headache—Bromocriptine—type 2 diabetes mellitus	0.000257	0.00191	CcSEcCtD
Phentolamine—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000256	0.00191	CcSEcCtD
Phentolamine—SIGMAR1—liver—type 2 diabetes mellitus	0.000254	0.0214	CbGeAlD
Phentolamine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000253	0.00189	CcSEcCtD
Phentolamine—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000253	0.00189	CcSEcCtD
Phentolamine—ADRA2A—pancreas—type 2 diabetes mellitus	0.00025	0.0211	CbGeAlD
Phentolamine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.00025	0.00186	CcSEcCtD
Phentolamine—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000248	0.00185	CcSEcCtD
Phentolamine—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000245	0.00183	CcSEcCtD
Phentolamine—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.000245	0.0207	CbGeAlD
Phentolamine—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000244	0.00182	CcSEcCtD
Phentolamine—Tachycardia—Losartan—type 2 diabetes mellitus	0.000244	0.00182	CcSEcCtD
Phentolamine—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000243	0.00182	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000243	0.00181	CcSEcCtD
Phentolamine—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000241	0.0018	CcSEcCtD
Phentolamine—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000241	0.0018	CcSEcCtD
Phentolamine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000238	0.00178	CcSEcCtD
Phentolamine—Vomiting—Glyburide—type 2 diabetes mellitus	0.000238	0.00178	CcSEcCtD
Phentolamine—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000238	0.00178	CcSEcCtD
Phentolamine—Headache—Glyburide—type 2 diabetes mellitus	0.000235	0.00175	CcSEcCtD
Phentolamine—Hypotension—Losartan—type 2 diabetes mellitus	0.000234	0.00174	CcSEcCtD
Phentolamine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.00023	0.00172	CcSEcCtD
Phentolamine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.00023	0.00172	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000229	0.00171	CcSEcCtD
Phentolamine—Pain—Irbesartan—type 2 diabetes mellitus	0.000227	0.00169	CcSEcCtD
Phentolamine—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000227	0.0192	CbGeAlD
Phentolamine—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000224	0.00167	CcSEcCtD
Phentolamine—Chest pain—Ramipril—type 2 diabetes mellitus	0.000224	0.00167	CcSEcCtD
Phentolamine—Nausea—Glyburide—type 2 diabetes mellitus	0.000223	0.00166	CcSEcCtD
Phentolamine—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000222	0.00166	CcSEcCtD
Phentolamine—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000222	0.00166	CcSEcCtD
Phentolamine—Asthenia—Valsartan—type 2 diabetes mellitus	0.000222	0.00165	CcSEcCtD
Phentolamine—Asthenia—Orlistat—type 2 diabetes mellitus	0.000219	0.00163	CcSEcCtD
Phentolamine—Pruritus—Valsartan—type 2 diabetes mellitus	0.000219	0.00163	CcSEcCtD
Phentolamine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000217	0.00162	CcSEcCtD
Phentolamine—Pruritus—Orlistat—type 2 diabetes mellitus	0.000216	0.00161	CcSEcCtD
Phentolamine—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000214	0.0016	CcSEcCtD
Phentolamine—Pain—Losartan—type 2 diabetes mellitus	0.000214	0.00159	CcSEcCtD
Phentolamine—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000211	0.00158	CcSEcCtD
Phentolamine—Headache—Gliclazide—type 2 diabetes mellitus	0.000211	0.00157	CcSEcCtD
Phentolamine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.00021	0.00157	CcSEcCtD
Phentolamine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.00021	0.00157	CcSEcCtD
Phentolamine—ADRA1A—liver—type 2 diabetes mellitus	0.000209	0.0177	CbGeAlD
Phentolamine—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000209	0.00156	CcSEcCtD
Phentolamine—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000209	0.00156	CcSEcCtD
Phentolamine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000204	0.00152	CcSEcCtD
Phentolamine—Dizziness—Valsartan—type 2 diabetes mellitus	0.000204	0.00152	CcSEcCtD
Phentolamine—Dizziness—Orlistat—type 2 diabetes mellitus	0.000202	0.00151	CcSEcCtD
Phentolamine—Asthenia—Metformin—type 2 diabetes mellitus	0.000202	0.00151	CcSEcCtD
Phentolamine—Hypotension—Ramipril—type 2 diabetes mellitus	0.0002	0.00149	CcSEcCtD
Phentolamine—Nausea—Gliclazide—type 2 diabetes mellitus	0.0002	0.00149	CcSEcCtD
Phentolamine—ADRA2C—liver—type 2 diabetes mellitus	0.000199	0.0168	CbGeAlD
Phentolamine—Pruritus—Metformin—type 2 diabetes mellitus	0.000199	0.00149	CcSEcCtD
Phentolamine—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000198	0.00147	CcSEcCtD
Phentolamine—Vomiting—Valsartan—type 2 diabetes mellitus	0.000196	0.00147	CcSEcCtD
Phentolamine—Vomiting—Orlistat—type 2 diabetes mellitus	0.000194	0.00145	CcSEcCtD
Phentolamine—Headache—Valsartan—type 2 diabetes mellitus	0.000194	0.00144	CcSEcCtD
Phentolamine—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000193	0.00144	CcSEcCtD
Phentolamine—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000192	0.00144	CcSEcCtD
Phentolamine—Headache—Orlistat—type 2 diabetes mellitus	0.000191	0.00143	CcSEcCtD
Phentolamine—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000191	0.00142	CcSEcCtD
Phentolamine—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000188	0.0014	CcSEcCtD
Phentolamine—Dizziness—Metformin—type 2 diabetes mellitus	0.000186	0.00139	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000185	0.00138	CcSEcCtD
Phentolamine—Nausea—Valsartan—type 2 diabetes mellitus	0.000184	0.00137	CcSEcCtD
Phentolamine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000182	0.00136	CcSEcCtD
Phentolamine—Nausea—Orlistat—type 2 diabetes mellitus	0.000181	0.00135	CcSEcCtD
Phentolamine—Asthenia—Losartan—type 2 diabetes mellitus	0.000179	0.00134	CcSEcCtD
Phentolamine—Vomiting—Metformin—type 2 diabetes mellitus	0.000179	0.00133	CcSEcCtD
Phentolamine—Pruritus—Losartan—type 2 diabetes mellitus	0.000177	0.00132	CcSEcCtD
Phentolamine—Headache—Metformin—type 2 diabetes mellitus	0.000176	0.00132	CcSEcCtD
Phentolamine—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000176	0.00131	CcSEcCtD
Phentolamine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000175	0.00131	CcSEcCtD
Phentolamine—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000171	0.00128	CcSEcCtD
Phentolamine—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000169	0.00126	CcSEcCtD
Phentolamine—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000169	0.00126	CcSEcCtD
Phentolamine—Nausea—Metformin—type 2 diabetes mellitus	0.000167	0.00125	CcSEcCtD
Phentolamine—Headache—Irbesartan—type 2 diabetes mellitus	0.000166	0.00124	CcSEcCtD
Phentolamine—Dizziness—Losartan—type 2 diabetes mellitus	0.000165	0.00123	CcSEcCtD
Phentolamine—Vomiting—Losartan—type 2 diabetes mellitus	0.000159	0.00119	CcSEcCtD
Phentolamine—Nausea—Irbesartan—type 2 diabetes mellitus	0.000158	0.00118	CcSEcCtD
Phentolamine—Headache—Losartan—type 2 diabetes mellitus	0.000157	0.00117	CcSEcCtD
Phentolamine—Asthenia—Ramipril—type 2 diabetes mellitus	0.000154	0.00115	CcSEcCtD
Phentolamine—Pruritus—Ramipril—type 2 diabetes mellitus	0.000152	0.00113	CcSEcCtD
Phentolamine—Nausea—Losartan—type 2 diabetes mellitus	0.000148	0.00111	CcSEcCtD
Phentolamine—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000147	0.00109	CcSEcCtD
Phentolamine—Dizziness—Ramipril—type 2 diabetes mellitus	0.000142	0.00106	CcSEcCtD
Phentolamine—Vomiting—Ramipril—type 2 diabetes mellitus	0.000136	0.00102	CcSEcCtD
Phentolamine—Headache—Ramipril—type 2 diabetes mellitus	0.000134	0.001	CcSEcCtD
Phentolamine—Nausea—Ramipril—type 2 diabetes mellitus	0.000127	0.00095	CcSEcCtD
Phentolamine—ADRA1D—Signaling Pathways—APOE—type 2 diabetes mellitus	7.27e-06	7.96e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—LEP—type 2 diabetes mellitus	7.27e-06	7.96e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—APOA1—type 2 diabetes mellitus	7.25e-06	7.93e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—GSTM1—type 2 diabetes mellitus	7.24e-06	7.92e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.22e-06	7.89e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—LPL—type 2 diabetes mellitus	7.2e-06	7.88e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.19e-06	7.86e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.16e-06	7.84e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—LPL—type 2 diabetes mellitus	7.11e-06	7.78e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	7.09e-06	7.76e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	7.09e-06	7.75e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—C3—type 2 diabetes mellitus	7.05e-06	7.72e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.05e-06	7.71e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—GNB3—type 2 diabetes mellitus	7.03e-06	7.69e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	6.96e-06	7.62e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—ADCY5—type 2 diabetes mellitus	6.96e-06	7.61e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	6.96e-06	7.61e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	6.93e-06	7.59e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AVP—type 2 diabetes mellitus	6.93e-06	7.58e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MMP3—type 2 diabetes mellitus	6.93e-06	7.58e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IGF2—type 2 diabetes mellitus	6.9e-06	7.55e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	6.87e-06	7.52e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.87e-06	7.51e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.86e-06	7.5e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	6.8e-06	7.44e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.76e-06	7.39e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	6.75e-06	7.39e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.74e-06	7.37e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.73e-06	7.36e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.71e-06	7.34e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AGT—type 2 diabetes mellitus	6.7e-06	7.33e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—APOB—type 2 diabetes mellitus	6.7e-06	7.33e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	6.67e-06	7.3e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—AKT1—type 2 diabetes mellitus	6.67e-06	7.3e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	6.67e-06	7.29e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.64e-06	7.26e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	6.59e-06	7.21e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.59e-06	7.21e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	6.59e-06	7.21e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—C3—type 2 diabetes mellitus	6.59e-06	7.21e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—LEP—type 2 diabetes mellitus	6.57e-06	7.18e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—APOE—type 2 diabetes mellitus	6.57e-06	7.18e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	6.53e-06	7.14e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.49e-06	7.1e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.49e-06	7.1e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—C3—type 2 diabetes mellitus	6.48e-06	7.09e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	6.44e-06	7.04e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	6.44e-06	7.04e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	6.41e-06	7.01e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	6.4e-06	7e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—LPL—type 2 diabetes mellitus	6.4e-06	7e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PPARG—type 2 diabetes mellitus	6.39e-06	6.99e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	6.38e-06	6.98e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	6.32e-06	6.91e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.28e-06	6.87e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	6.28e-06	6.87e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.27e-06	6.86e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—INS—type 2 diabetes mellitus	6.27e-06	6.85e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	6.26e-06	6.85e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AGT—type 2 diabetes mellitus	6.26e-06	6.85e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—AKT1—type 2 diabetes mellitus	6.23e-06	6.82e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	6.22e-06	6.81e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—INS—type 2 diabetes mellitus	6.21e-06	6.8e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	6.2e-06	6.78e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.19e-06	6.77e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.18e-06	6.76e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.17e-06	6.75e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AGT—type 2 diabetes mellitus	6.16e-06	6.74e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.16e-06	6.73e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—LEP—type 2 diabetes mellitus	6.13e-06	6.71e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—APOE—type 2 diabetes mellitus	6.13e-06	6.71e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	6.13e-06	6.7e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.11e-06	6.69e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	6.08e-06	6.65e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.06e-06	6.63e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.06e-06	6.63e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—APOE—type 2 diabetes mellitus	6.04e-06	6.6e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—LEP—type 2 diabetes mellitus	6.04e-06	6.6e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.01e-06	6.57e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.01e-06	6.57e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6e-06	6.57e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.98e-06	6.54e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	5.98e-06	6.54e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.97e-06	6.53e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	5.96e-06	6.52e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	5.94e-06	6.5e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.89e-06	6.45e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	5.89e-06	6.44e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.86e-06	6.41e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.82e-06	6.36e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.78e-06	6.33e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	5.76e-06	6.3e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—ALB—type 2 diabetes mellitus	5.75e-06	6.28e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.71e-06	6.24e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.69e-06	6.23e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—INS—type 2 diabetes mellitus	5.61e-06	6.14e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.58e-06	6.1e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.52e-06	6.04e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3R1—type 2 diabetes mellitus	5.5e-06	6.01e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—NOS3—type 2 diabetes mellitus	5.5e-06	6.01e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.49e-06	6.01e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.48e-06	5.99e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.48e-06	5.99e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	5.47e-06	5.99e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.47e-06	5.99e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.45e-06	5.96e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.45e-06	5.96e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.43e-06	5.94e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.42e-06	5.93e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.4e-06	5.91e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.39e-06	5.89e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.38e-06	5.89e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	5.36e-06	5.87e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	5.36e-06	5.87e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	5.35e-06	5.85e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.3e-06	5.8e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—INS—type 2 diabetes mellitus	5.24e-06	5.73e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	5.19e-06	5.68e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—INS—type 2 diabetes mellitus	5.16e-06	5.64e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.16e-06	5.64e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.15e-06	5.64e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—RELA—type 2 diabetes mellitus	5.13e-06	5.61e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.1e-06	5.58e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.09e-06	5.57e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	5.09e-06	5.57e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	5.08e-06	5.56e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.07e-06	5.55e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.07e-06	5.54e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.06e-06	5.54e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	5.06e-06	5.54e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.06e-06	5.53e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.04e-06	5.52e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTGS2—type 2 diabetes mellitus	5.03e-06	5.5e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	5e-06	5.47e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.99e-06	5.46e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.98e-06	5.45e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	4.98e-06	5.45e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	4.98e-06	5.45e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.96e-06	5.43e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.92e-06	5.39e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.92e-06	5.38e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.92e-06	5.38e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.81e-06	5.26e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.78e-06	5.23e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.74e-06	5.18e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.7e-06	5.14e-05	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.67e-06	5.11e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	4.67e-06	5.1e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	4.63e-06	5.06e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.63e-06	5.06e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.6e-06	5.03e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.6e-06	5.03e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.6e-06	5.03e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	4.58e-06	5.01e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.52e-06	4.95e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.52e-06	4.95e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.51e-06	4.93e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	4.46e-06	4.88e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	4.46e-06	4.88e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.44e-06	4.86e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.43e-06	4.85e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.43e-06	4.84e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.41e-06	4.82e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.37e-06	4.78e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	4.33e-06	4.73e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.33e-06	4.73e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—RELA—type 2 diabetes mellitus	4.26e-06	4.66e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	4.26e-06	4.66e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.24e-06	4.64e-05	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.22e-06	4.61e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.21e-06	4.6e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.19e-06	4.58e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.18e-06	4.57e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.15e-06	4.54e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.12e-06	4.5e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.11e-06	4.5e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.1e-06	4.48e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	4.08e-06	4.47e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—SRC—type 2 diabetes mellitus	4.03e-06	4.41e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.02e-06	4.39e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.02e-06	4.39e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.95e-06	4.32e-05	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.94e-06	4.31e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.93e-06	4.29e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.91e-06	4.28e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.91e-06	4.27e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.9e-06	4.27e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.88e-06	4.24e-05	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.88e-06	4.24e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.84e-06	4.2e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.83e-06	4.19e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.81e-06	4.17e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	3.78e-06	4.14e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.73e-06	4.08e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.73e-06	4.08e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.69e-06	4.03e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.65e-06	3.99e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	3.64e-06	3.98e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.63e-06	3.97e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.6e-06	3.94e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.59e-06	3.93e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.58e-06	3.91e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.54e-06	3.88e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.53e-06	3.86e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.52e-06	3.85e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	3.51e-06	3.84e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.44e-06	3.77e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.41e-06	3.73e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	3.4e-06	3.72e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.39e-06	3.71e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	3.35e-06	3.66e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.31e-06	3.62e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.26e-06	3.56e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.25e-06	3.56e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.22e-06	3.53e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.2e-06	3.5e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.19e-06	3.49e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.19e-06	3.49e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.17e-06	3.47e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.15e-06	3.44e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.13e-06	3.42e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.04e-06	3.32e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.99e-06	3.28e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.99e-06	3.27e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.98e-06	3.26e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.97e-06	3.25e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.96e-06	3.24e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.93e-06	3.21e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.9e-06	3.18e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.89e-06	3.17e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.76e-06	3.02e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL6—type 2 diabetes mellitus	2.72e-06	2.97e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.69e-06	2.94e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.66e-06	2.91e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.6e-06	2.85e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	2.53e-06	2.76e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.5e-06	2.74e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.47e-06	2.7e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	2.45e-06	2.68e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.42e-06	2.65e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	2.29e-06	2.5e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.26e-06	2.47e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	2.25e-06	2.46e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.11e-06	2.31e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.08e-06	2.27e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	2.05e-06	2.24e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2e-06	2.19e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.86e-06	2.03e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.85e-06	2.02e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.72e-06	1.88e-05	CbGpPWpGaD
